Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox...
Tuesday, January 22, 8:59 AM ETCelsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles